1)Raval AN, et al:Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting;A scientific statement from the American Heart Association. Circulation 135:e604-e633, 2017
2)Douketis JD, et al:Perioperative management of antithrombotic therapy;Antithrombotic Therapy and Prevention of Thrombosis, 9th ed;American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e326S-e350S, 2012
3)Dubois V, et al:Perioperative management of patients on direct oral anticoagulants. Thromb J 15:14, 2017
4)Piccini JP, et al:Management of major bleeding events in patients treated with rivaroxaban vs. warfarin;Results from the ROCKET AF trial. Eur Heart J 35:1873-1880, 2014
5)Douketis JD, et al:Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost 113:625-632, 2015
6)Sarode R, et al:Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding;Arandomized, plasma-controlled, phase Ⅲb study. Circulation 128:1234-1243, 2013
7)Hickey M, et al:Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation 128:360-364, 2013
8)Connolly SJ, et al:Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375:1131-1141, 2016